Guiding patients through their journey with Optune (Tumour-Treating Fields) comes with unique considerations, but you’re not alone. Our resources are designed to support clinicians like you - offering expert guidance, practical information and a collaborative community to help you provide the best care for your patients.
This website is designed to help patients learn about Optune and access it more easily. As part of this, we also aim to simplify the prescribing process for clinicians.
Optune (Tumour Treating Fields) is an FDA-approved, CE-marked medical device licensed for the treatment of glioblastoma (GBM), mesothelioma and non-small cell lung cancer.
1
Prescribing Optune is straightforward:
2
Novocure must be paid through an established healthcare provider (e.g., a hospital):
3
If your hospital does not yet have a contract with Novocure:
4
While this process may seem complex, it is typically straightforward. Optune has strong clinical evidence, is CE-marked, and is widely used, making approval likely.
Contracting can take longer, as Novocure must be formally registered as a supplier.
If you need support with this process (e.g., accessing local New Procedures paperwork), please get in touch via the contact form below – we’re happy to help.